First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC
Eli Lilly and Company
Caicun Zhou; Benjamin Solomon; Herbert H Loong; Keunchil Park; Maurice Pérol; Edurne Arriola; Silvia Novello; Baohui Han; Jianying Zhou; Andrea Ardizzoni; M Perez Mak; Fernando C Santini; Yasir Y Elamin; Alexander Drilon; Jürgen Wolf; Nalin Payakachat; Minji K Uh; Deborah Rajakumar; Hongmei Han; Tarun Puri; Victoria Soldatenkova; A Bence Lin; Boris K Lin; Koichi Goto; LIBRETTO-431 Trial Investigators